PTO/S8/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449A/B/PTO 10/730549 Application Number **INFORMATION DISCLOSURE** December 5, 2003 Filing Date STATEMENT BY APPLICANT Mary J. Laughlin First Named Inventor Art Unit N/A (Use as many sheets as necessary) Not Yet Assigned Examiner Name CWRU-P01-046 Sheet 1 of 5 Attorney Docket Number

T			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
leb	AA	US-2003/0064519	05-30-2002	Bruder et al.	
	AB	US-6,387,367	05-14-2002	Davis-Sproul et al.	
	AC	US-5,733,542	03-31-1998		
	AD	US-6,010,696	01-04-2000	Caplan et al.	
	AE	US-5,591,625	01-07-1997	Gerson et al.	
	AF	US-2003/0180705	09-25-2003	Murohara et al.	
	AG	US-2003/0152558	08-14-2003	Luft et al.	
	AH	US-5,486,359	01-23-1996	Caplan et al.	
	AI	US-2003/0148952	08-07-2003	Crombreholme et al.	
	AJ	US-2004/0131585	07-08-2004	Itescu	
	AK	US-5,612,211	03-18-1997	Wilson et al.	
	AL	US-5,652,225	07-29-1997	Isner	
	AM	US-2003/0199464	10-23-2003	Itescu	
	AN	US-6,676,937	01-13-2004	Isner et al.	
	AO	US-2003/0232050	12-18-2003	Isner et al.	
	AP	US-2001/0051372	12-13-2001	Yin et al.	
	AQ	US-5,843,633	12-01-1998	Yin et al	
	AR	US-6,586,192	07-01-2003	Peschle et al.	
	AS	US-2002/0051762	05-02-2002	Rafii et al.	
	AT	US-2002/0164794	11-07-2002	Wernet	
	AU	US-2003/0148512	08-07-2003	Fanslow, III et al.	
	AV	US-2002/0168765	11-14-2002	Prockop et al.	
	AW	US-6,387,369	05-14-2002	Pittenger et al.	
	AX	US-6,461,645	10-08-2002	Boyse et al.	
	AY	US-6,429,012	08-06-2002	Kraus et al.	
	AZ	US-5,654,186	08-05-1997	Cerami et al.	
	AAA	US-2003/0091547	05-15-2003	Edelberg et al.	· · · · · · · · · · · · · · · · · · ·
	ABB	US-5,980,887	11-09-1999	Isner et al.	

			FOREI	GN PATENT	DOCUMENTS	
Exam		Cite	Foreign Patent Document	Publication		Columns, Lines, elevant Passages
Initials		No.1	Country Code ³ -Number ⁴ -Kind Code ⁴ (if known)	Date MM-DD-YYYY		ant Figures Appear
	-	BA	WO 89/03875	05-05-1989	Thomas Jefferson University	
		ВВ	WO 92/07573 05-14-1992 Somatix Therapy Corporation		Somatix Therapy Corporation	
		ВС	WO 93/13807	07-22-1993	Georgetown University	
		BD	WO 96/06933	03-07-1996	Sandoz Ltd.	
		BE	WO 97/12519	04-10-1997	St. Elizabeth's Medical Center	
			·		of Boston, Inc.	
		BF	WO 97/30083	08-21-1997	Novartis AG	
		BG	WO 99/37751	07-29-1999	Imclone Systems Incorporated	
	/	вн	WO 01/94420	12-13-2001	The Trustees of Columbia University in the City of New York	
		ВІ	WO 03/078610	09-25-2003	Miltenyi Biotec GMBH	<u></u>
Exan	nino	. 1		<u> </u>	Date	
Signa			/Lora E Barnhart	/	Considered 10	/30/2006

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	bstitute for form 1449A/B/PT			Complete if Known		
30.	James Iol Ioliii 144074011 1		,	Application Number	10/730549	
- 11	NFORMATION	1 DI	SCLOSURE	Filing Date	December 5, 2003	
5	STATEMENT E	3Y /	APPLICANT	First Named Inventor	Mary J. Laughlin	
	, , , , , , , , , , , , , , , , , , ,			Art Unit	N/A	
1	(Use as many she	aets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	5	Attorney Docket Number	CWRU-P01-046	

\Box	eb	BJ	WO 99/37751	07-29-1999	Imclone Systems Incorporated	
		ВК	WO 03/095631		Fondazione Centro San Raffaele Del Monte Tabor	
	Н	BL	WO 00/12683		New York University	
		ВМ	WO 03/070083	08-28-2003	Cornell Research Foundation	

EXAI INER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicants unique citation designation number (optional). See Kinds Codes of USPT Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Transition is attached.

		NON PATENT LITERATURE DOCUMENTS	
Exam er Initial	Cite No. ¹	magazine, jour nal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	OSMAN et al., "Cardiac Cell Transplantation: Closer to Bedside", Ann Thorac Surg 2003; 75: S674-7	
	СВ	MINGUELL et al., "Biology and clinical utilization of mesenchymal progenitor cells", Braz J Med Biol Res, 2000, 33(3):881-887	
	СС	MINGUELL et al., "Mesenchymal Stern Cells", Exp Biol Med Vol. 226(6):507-520.	
	CD	SUKHIKH et al., "Mesenchymal Stem Cells", Bulletin of Experimental Biology and Medicine, 2002, 133(2):103-109	
	CE	FIBBE et al., "Mesenchymal Stem Cells and Hematopoietic Stem Cell Transplantation", 2003, Ann. N.Y. Acad Sci, 996:235-244	
	CF	VILKIN et al., "Cell Transplantation for Post-Ischemic Heart Failure", Archives des Maladies du Coeur et des Vaisseaux, 2002, 95(12):1219-1225	
	CG	ITESCU et al., "Myocardial Neovascularization by Adult Bone Marrow-Derived Angioblasts: Strategies for Improvement of Cardiomyocyte Function", Ann Hematol. 2002;81 Suppl 2:S21-S25	
	СН	YANG et al. Zhonghua Yi Xue Za Zhi, "Transplantation of cord blood endothelial progenitor cells ameliorates limb ischemia" 2003, 83(16) (Abstract)	
	CI	ERICES et al., "Human cord-blood-derived mesenchymal stem cells home and survive in the marrow of immunodeficient mice after systemic infusion", Cell Transplant, 2003, 12(6):555-61.	
	C1	RAFII et al., "Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration", Nature Medicine, 2003, 9(3):702-712	
	СК	ANKER et al., "Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOS/SCID mice", Exp Hematol. 2003. 31(10)	
	CL	RODRIGUEZ-MANZANEQUE et al., "Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor", PNAS, 2001, 98(22):12485-12490	
	СМ	WYNTER et al., "CD34+AC133+ Cells Isolated from Cord Blood are Highly Enriched in Long- Term Culture-Initiating Cells, NOD/SCID-Repopulating Cells and Dendritic Cell Progenitors, Stem Cells, 1998, 16:387-396.	
7	CN	BURT et al., "Hematopoietic stem cell transplantation for cardiac and peripheral vascular disease", Bone Marrow Transplantation, 2003, 32:S29-S31.	
─ ¥	co	LAZARUS et al., "Human Bone Marrow-Derived Mesenchymal (Stomal) Progenitor Cells	

Examiner	/Tone B Dombont /	Date	10/30/2006
Signature	/Lora E Barnhart/	Considered	10/30/2006

	Under the Paperwo	rk Reducti	on Act of 1995, no persons are rec	U.S. Patent and Tra	PTO/SB/08a/b (08-03) oproved for use through 07/31/2006. OMB 0651-0031 idemark Office; U.S. DEPARTMENT OF COMMERCE information unless it contains a valid OMB control number.
Cul	stitute for form 1449A/B/P	τo			Complete If Known
300	SUIDER TO TOTAL 1440-2011			Application Number	10/730549
110	FORMATIO	N DI	SCLOSURE	Filing Date	December 5, 2003
	TATEMENT			First Named Inventor	Mary J. Laughlin
~	17.12			Art Unit	N/A
	(Use as many st	ne ets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	3	of	5	Attorney Docket Number	CWRU-P01-046

		(MPCs) Cannot Be Recovered from Peripheral Blood Progenitor Cell Collections", Journal of Hematotherapy, 1997, 6:447-455.								
leb	СР	LAZARUS et al., "Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use", Bone Marrow Transplantation, 1995, 16:557-564								
T	ca	JAISWAL et al., "Osteogenic Differentiation of Purified, Culture-Expanded Human Mesenchymal Stem Cells In Vitro", Journal of Cellular Biochemistry, 1997, 64:295-312.								
	CR	TATEISHI-YUYAMA et al., "Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial." The Lancet, 2002, 360:427-435								
	cs	KOC et al., "Rapid Hematopoietic Recovery After Coinfusion of Autologous-Blood Stem Cells and Culture-Expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-Dose Chemotherapy", Journal of Clinical Oncology, 2000, 18(2):307-316.								
1	СТ	ANKOMA-SEY et al. (1998). "Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing." Oncogene 17(1): 115-21.								
	cu	ASAHARA et al. (1999). "Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization." Circ Res 85(3): 221-28.								
	CV	ASAHARA et al (1999). "VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells." EMBO J 18(14): 3964-72.								
	cw	BARRY F et al. (2001). "The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells." Biochem Biophys Res Commun 289(2): 519-24.								
	СХ	BARRY FP et al. (1999). "The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105)." Biochem Biophys Res								
	CY	CHAUHAN A et al. (1996). "Aging-associated endothelial dysfunction in humans is reversed by Lagraining." J. Am Coll Cardiol 28(7): 1796-1804.								
1	CZ	CHENG T., (2002). "Cell cycle entry of hematopoietic stem and progenitor cells controlled by distinct cyclin-dependent kinase inhibitors." Int J Hematol 75(5): 460-5								
	CAA	D'APUZZO et al. (1997). "The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4." Eur J Immunol 27(7): 1788-93								
	СВВ	FLEMING et al. (1998). "Monoclonal antibody against adult márrow-derived mesenchymal stem cells recognizes developing vasculature in embryonic human skin." Dev Dyn 212(1): 119-								
	ccc	GEHLING et al. (2000). "In vitro differentiation of endothelial cells from AC133-positive progenitor cells." Blood 95(10): 3106-12								
	CDD	GILL et al. (2001). "Vascular trauma induces rapid but transient mobilization of VEGER2(+)AC133(+) endothelial precursor cells." Circ Res 88(2): 167-74								
	CEE	GU et al. (2000). "Association of extracellular matrix proteins fibulin-1 and fibulin-2 with fibropectin in hone marrow stroma." Br J Haematol 109(2): 305-13								
1	CFF	HARTLAPP et al. (2001). "Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo." FASEB J 15(12): 2215-24								
1	cgg	HAYNESWORTH et al. (1996). "Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha." J Cell Physiol 166(3): 585-								
T	снн	HAYNESWORTH et al. (1992). "Characterization of cells with osteogenic potential from human marrow " Bone 13(1): 81-8								
1,	CII	KALKA et al. (2000). "Transplantation of ex vivo expanded endothelial progenitor cells for the rapeutic people scularization." Proc. Natl. Acad Sci. U.S. A. 97(7): 3422-7								
₩-	C11	KAWAMOTO et al. (2001). "Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia." Circulation 103: 634-637								
kamin gnatu		/Lora E Barnhart/ Date Considered 10/30/2006								

no date

tinder the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

S.,,	ostitute for form 1449A/B/PT	· ·		Complete If Known		
Sui	15111010 101 101111 1440700F 1	•		Application Number	10/730549	
11	NFORMATION	l DI	SCLOSURE	Filing Date	December 5, 2003	
	TATEMENT !			First Named Inventor	Mary J. Laughlin	
				Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	4	of	5	Attorney Docket Number	CWRU-P01-046	

Copy of international search report from corresponding PGT Application No. PCT/US03/38060 1 CHR KLEIN et al. (1995). "Collagen type VI in the human bone marrow microenvironment: a strong CLL cytoadhesive component." Blood 86(5): 1740-8 leb LAUGHLIN et al. (2001). "Hematopoietic engraftment and survival after unrelated donor СММ umbilical cord blood (UCB) transplantation in adult recipients." New Engl J Med 344(24): 1815-MANDEL et al. (2001). "Isolation and Culture Expansion of Endothelial Progenitor Cells From CNN UCB Using a Simple Selection Process." Blood 98(11): 55b (Abstract) OHTA et al. (1998). "Suppression of hematopoietic activity in tenascin-C-deficient mice." Blood COO 91(11): 4074-83 PIERELLI et al. (2001). "CD105 (endoglin) expression on hematopoletic stem/progenitor CPP cells." Leuk Lymphoma 42(6): 1195-206 RIBATTI et al. (1995). "Endogenous basic fibroblast growth factor is implicated in the COO vascularization of the chick embryo chorioallantoic membrane." Dev. Biol. 170: 39-49
RUBINSTEIN et al. (1998). "Outcomes among 562 recipients of placental-blood transplants CRR from unrelated donors [see comments]." New England Journal of Medicine 339(22): 1565-1577 SHI et al. (1999). "Evidence for circulating bone marrow-derived endothelial cells." Blood 92: CSS 362-367 TSCHUDI et al. (1996). "Effect of age on kinetics of nitric oxide release in rat aorta and CTT pulmonary artery." J Clin Invest 98(4): 899-905 CUU WANG et al. (2002). "Receptor tyrosine kinase, EphB4 (HTK), accelerates differentiation of select human hematopoietic cells." Blood 99(8): 2740-7 ZHANG X et al. (2001). "Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia." Cancer Res 61(16): 6050-4 YIN et a. (1997). "AC133, a Novel Marker for Human Hematopoietic Stem and Progenitor CWW Cells." Blood 90(12):5002-12 BUHRING et al. "Expression of Novel Surface Antigens on Early Hematopoietic Cells." (1999) CXX Ann NY Accad SCI 99 872:25-39 MAJKA et al. "Expression, regulation and function of AC133, a putative cell surface marker of CYY primitive human haematopoetic cells." (2000) Folia Histochem Cytobiol. 38:53-63 ERICES et al. "Mesenchymal progenitor cells in human umbilical cord blood." (2000) Br. J CZ7 Haematol 109(1):235-42 STRAUER B et al. "Repair of Infarcted Myocardium by Autologous Intracoronary Mononuclear CAAA Bone Marrow Cell Transplantation in Human." (2002) Circulation 1913-1918 ASSMUS B et al. "Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)." (2002) Circulation 106:3009-3017 CRRR AMRANI D et al. "Cardiovascular disease: potential impact of stem cell therapy." (2003) Expert CCCC Reu. Cardiovasc. Ther. 1(3), 453-461 HRISTOV, M et al. "Endothelial Progenitor Cells." (2003) Arterioscler Thromb Vasc Biol. 1185-CDDD 1189. STAMM, C et al. "Autologous bone-marrow stem-cell transplantation for myocardial CEEE regeneration." (2003) The Lancet, Vol. 361. 45-46 KAWAMOTO, A et al. "Tranplantation of endothelial progenitor cells for therapeutic neovascularization." (2002) Cardiovascular Radiation Medicine 3, 221-225 MUROHARA, T et al. "Transplanted cord blood-derived endothelial precursor cells augment CGGG postnatal neovascularizaton." (2000) The Journal of Clinical Investigation Vol. 105, No. 11, 1527-1536 REHMAN, J et al. "Peripheral Blood "Endothelial Progenitor Cells" Are Derived From Monocyte/Macrophages and Secrete Angiogenic Growth Factors." (2003) Circulation, 1164-Examiner /Lora E Barnhart/ 10/30/2006 Considered Signature

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ersons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/	ra/PTO		Complete If Known		
3003000	1011011111144074	5.7 . 5		Application Number	10/730549	
INFO	DRMATI	ON DISC	CLOSURE	Filing Date	December 5, 2003	
STA	TEMEN'	T BY AF	PLICANT	First Named Inventor	Mary J. Laughlin	
• • • • • • • • • • • • • • • • • • • •				Art Unit	N/A	
	(Use as man	y sheets as ne	cessary)	Examiner Name	Not Yet Assigned	
Sheet	5	of	5	Attorney Docket Number	CWRU-P01-046	

leb	CIII	YANG, C et al. "Enhancement of neovascularization with cord blood CD133+ cell-derived endothelial progenitor cell transplantation." (2003) Vascular Development and Vessel Remodeling, 1202-1212	
1	C111	GOUSSETIS, E. et al. "Kinetics of quiescent cord blood stern/progenitor cells with high proliferative potential in stem-cell expansion culture." 1: Cytotherapy, 2003; 5(6): 500-8	
	СККК	BOXBERGER, O et al. "Mesenchymal stem cells can be differentiated into endothelial cells in vitro." 1: Stem Cells, 2004; 22(3):377-84	
T	CLLL	TULI, R et al. "Characterization of multipotential mesenchymal progenitor cell derived from human trabecular bone." 1: Stem Cells, 2003; 21(6):681-93	_
		SUVA, D. et al. "Non-hematopoietic human bone marrow contains long-lasting, pluripotential mesenchymal stem cells." 1: J Cell Physiol. 2004 Jan; 198(1):110-8	
	CNNN	KUWANÁ, M. et al. "Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation." 1: J Leukoc Biol. 2003 Nov; 74(5):833-45 (Abstract only)	
		COVAS, D.T. et al. "Isolation and culture of umbilical vein mesenchymal stem cells." 1: Braz J Med Biol Res. 2003 Sep; 26(9): 1179-83 (Abstract only)	
		HAO, S.G, et al. "Studies on the dynamics of biological characteristics of CD133+ cells from human umbilical cord blood during short-term culture." 1:Zhongguo Shi Yan Zue Ye Xue Za Zhi. 2003 Dec; 11(6):569-75 (Abstract only)	
1		CHEN, J et al. "Number of activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolemia." 1: Clin Sci (Lond). 2004 Apr 20	
V	CRRR	BURGER et al. " Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells" <i>Blood</i> . 2002 15;100(10):3527-35	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	. <u> </u>		
Examiner		Date	10/30/2006
Signature	/Lora E Barnhart/	Considered	10/30/2006

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.



PTO/S8/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	stitute for form 1449A/B/PT	0		Complete If Known		
				Application Number	10/730549	
11	NFORMATION	I DI	SCLOSURE	Filing Date	December 5, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Mary J. Laughlin	
				Art Unit	1651	
	(Use as many sheets as necessary)			Examiner Name	L. B. Lankford	
Sheet	1	of	1	Attorney Docket Number	CWRU-P01-046	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۲۰		
						Γ		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the No.1 (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), particle (when appropriate), title of the article (when appropr		T²
leb	CSSS	FINNEY, et al, "Comparison of Umbilical Cord Blood Versus Bone Marrow-Derived Endothelial Precursor Cells in Mediating Neovascularization in a NOD/SCID Hind limb injury Model", (2002)	
	стт	FINNEY, et al, "Umbilical Cord Blood versus Adult Bone Marrow-Derived Endothelial Precursor Cells (EPCs): In Vitro Characteristics and effectiveness in Vivo in Mediating Neovascularization after Femoral Artery Injury", Scientific Sessions. (2003).	
	CUUU	LODIE, et al, "Systematic Analysis of Reportedly Distinct Populations of Multipotent Bone Marrow-Derived Stem Cells Reveals a Lack of Distinction", Tissue Engineering, vol. 8, number 5, 739-751 (2002).	
	cvvv	SCHMEISSER, et al, "Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel® under angiogenic conditions", Cardiovascular Research, vol. 49, 671-680 (2001).	
	cwww	MA NAN, et al, "Human cord blood cells induce and angiogenesis following myocardial infarction in NOD/scid-mice", Cardiovascular Research vol. 66 no. 1, 45-54 (2005).	
_ V	CXXX	HRISTOV, et al, "Endothelial progenitor cells: isolation and characterization", Trends in Cardiovascular Medicine, Vol. 13, no. 5, 2001-2006, (2003).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Lora E Barnhart/	Date Considered	10/30/2006
			0072400 4 0000

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

APR 2 6 2006

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Application Number 10/730549

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

Complete If Known					
Application Number	10/730549				
Filing Date	December 5, 2003				
First Named Inventor	Mary J. Laughlin				
Art Unit	1651				
Examiner Name	L. B. Lankford				
Attorney Docket Number	CWRU-P01-046				

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-OD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS							
İ	Evaminar	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
	Examiner Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ³ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	To	
	leb	BN	WO-01/93909	12-13-2001	Glaxo Group Limited			
۱ ا	b .	во	WO-03/087333	10-23-2003	Cel-Gene Corporation			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspic.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cité No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
leb	CYYY	Dragulescu, S. I., et al., "Protocol For Intracoronary Transplantation of Autologous AC133 Bone Marrow Stem Cells," TMJ, 54(1):14-18 (2004).				
leb	CZZZ	Peichev, M., et al., "Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors," Blood, 95(3):952-958 (Feb. 1, 2000).				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Lora E Barnhart/	Date	10/30/2006
Signature	/ DOTA B DATIMATE/	Considered	20,00,200

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.